• Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas 

      Fack, Fred; Espedal, Heidi; Keunen, Olivier; Golebiewska, Anna; Obad, Nina; Harter, Patrick N.; Mittelbronn, Michel; Bähr, Oliver; Weyerbrock, Astrid; Stuhr, Linda Elin Birkhaug; Miletic, Hrvoje; Sakariassen, Per Øystein; Stieber, Daniel; Rygh, Cecilie Brekke; Lund-Johansen, Morten; Zheng, Liang; Gottlieb, Eyal; Niclou, Simone P.; Bjerkvig, Rolf (Peer reviewed; Journal article, 2015-01)
      Anti-angiogenic therapy in glioblastoma (GBM) has unfortunately not led to the anticipated improvement in patient prognosis. We here describe how human GBM adapts to bevacizumab treatment at the metabolic level. By performing ...
    • Impact of Docetaxel on blood-brain barrier function and formation of breast cancer brain metastases 

      Bernatz, Simon; Ilina, Elena I.; Devraj, Kavi; Harter, Patrick N.; Mueller, Klaus; Kleber, Sascha; Braun, Yannick; Penski, Cornelia; Renner, Christoph; Halder, Rashi; Jennewein, Lukas; Solbach, Christine; Thorsen, Frits; Pestalozzi, Bernhard C.; Mischo, Axel; Mittelbronn, Michael (Peer reviewed; Journal article, 2019-10-29)
      Background: Breast cancer (BC) is the most frequent malignant tumor in females and the 2nd most common cause of brain metastasis (BM), that are associated with a fatal prognosis. The increasing incidence from 10% up to 40% ...
    • Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis 

      Sundstrøm, Terje; Prestegarden, Lars; Azuaje, Francisco; Aasen, Synnøve Nymark; Røsland, Gro Vatne; Varughese, Jobin K.; Bahador, Marzieh; Bernatz, Simon; Braun, Yannick; Harter, Patrick N.; Skaftnesmo, Kai Ove; Ingham, Elizabeth S.; Mahakian, Lisa M.; Tam, Sarah; Tepper, Clifford G.; Petersen, Kjell; Ferrara, Katherine W.; Tronstad, Karl Johan; Lund-Johansen, Morten; Beschorner, Rudi; Bjerkvig, Rolf; Thorsen, Frits (Peer reviewed; Journal article, 2019-04-10)
      Melanoma patients carry a high risk of developing brain metastases, and improvements in survival are still measured in weeks or months. Durable disease control within the brain is impeded by poor drug penetration across ...
    • Targeting APLN/APLNR improves antiangiogenic efficiency and blunts proinvasive side effects of VEGFA/VEGFR2 blockade in glioblastoma 

      Mastrella, Giorgia; Hou, Mengzhuo; Li, Min; Stöcklein, Veit M.; Zdouc, Nina; Volmar, Marie N.M.; Miletic, Hrvoje; Reinhard, Sören; Herold-Mende, Christel C.; Kleber, Susanne; Eisenhut, Katharina; Gargiulo, Gaetano; Synowitz, Michael; Vescovi, Angelo L.; Harter, Patrick N.; Penninger, Josef M.; Wagner, Ernst; Mittelbronn, Michel; Bjerkvig, Rolf; Hambardzumyan, Dolores; Schüller, Ulrich; Tonn, Jörg Christian; Radke, Josefine; Glass, Rainer; Kälin, Roland E. (Peer reviewed; Journal article, 2019)
      Antiangiogenic therapy of glioblastoma (GBM) with bevacizumab, a VEGFA-blocking antibody, may accelerate tumor cell invasion and induce alternative angiogenic pathways. Here we investigate the roles of the proangiogenic ...